The Campbell’s Company (NASDAQ:CPB) is taking aggressive steps to turn around its fortunes, but the food company faces a difficult test. It’s whether the $500 million cost-savings plan can rebuild margins and earnings as weak demand continues to pressure sales.
The company has already cut more than 550 jobs and closed two snack plants as part of the cost-cutting efforts. Moreover, it has reduced its quarterly dividend by 36% to conserve cash. Yet management expects another year of declining sales. That means the turnaround hinges on Campbell’s ability to improve efficiency while stabilizing sales.
Campbell’s Is Betting on Cost Cuts to Rebuild Margins
The need for restructuring became clear in the latest quarter. Sales fell 8% to $2.1 billion, and the company swung to a $69 million loss from a $145 million profit a year ago.
The Campbell’s Company now plans to cut $500 million in costs by fiscal 2030. The savings are expected to support margin and allow greater investment in the brands. The cost-cutting program includes the closure of two snack plants and a workforce reduction affecting around 13% of Campbell’s salaried employees.
Campbell’s strategy has a clear financial logic. Lower costs should improve cash flow, help the company absorb inflationary pressures, and provide greater flexibility to invest in strengthening its brands. But the desired turnaround would only be possible if Campbell’s can stabilize its underlying business at the same time.
Snacks Remains the Biggest Problem
Campbell’s Snacks division, which includes Goldfish crackers and Cape Cod potato chips, saw sales plunge 12% in the quarter. But the Meals and Beverages segment was more resilient as sales declined only 4%.
The weakness highlights the central risk to Campbell’s turnaround bid. Persistent inflation has made consumers more cautious. The company plans to selectively raise prices to offset commodity costs while lowering prices in other areas. However, management has acknowledged that pricing actions could pressure volumes in the near term.
That creates a difficult balancing act. Campbell’s needs pricing and productivity savings to protect margins, yet aggressive pricing could further weaken demand. And steady volume declines could erode the financial benefits generated by restructuring.
Campbell’s guidance reflects that uncertainty. The company expects fiscal 2027 adjusted EPS in the range of $1.65 to $1.80. That’s below analysts’ estimate of $1.83. Campbell’s also expects net sales to decline 2% to 4%, worse than analysts’ forecast of roughly a 1% decline.
Investors Are Betting on a Turnaround, But Shorts Remain Skeptical
Institutional positioning suggests some investors were already seeing value in Campbell’s shares before the latest restructuring plan was announced. The number of hedge funds in Campbell’s increased to 31 in Q2 from 26 in Q1.
Several major funds increased their positions sharply in the stock. AQR Capital Management raised its stake by 221% to 4.1 million shares, after already increasing it 76% in Q1 and 22% in Q4. Quantinno Capital increased its position 142% to 3.2 million shares, while Gotham Asset Management raised its stake 301% to 1.8 million shares.
However, the market remains divided. As of August 14, some 41.8 million Campbell’s shares were sold short, representing 17.47% of the public float. Although short interest declined 13.33% from the previous report, the remaining position equates to 9.1 days to cover, indicating substantial bearish positioning.
Campbell’s Must Prove Savings Can Outrun Sales Decline
The Campbell’s Company has outlined its turnaround plan, but a plan is not the same as results. The bullish case rests on cost reductions improving margins and cash flow while arresting sales decline. The bear case is that persistent volume weakness, particularly in Snacks, absorbs those gains before they reach the bottom line.
If Campbell’s can stabilize sales and the restructuring program delivers sustained margin improvement, the stock could begin to reflect a credible recovery. Conversely, if sales slide faster than costs can be removed, the $500 million savings target may prove insufficient to reverse the company’s trajectory.
READ NEXT: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb and Cenovus (CVE) Enters the Ranks of the World’s Largest Oil and Gas Producers
Hedge Fund Resource Center